The health impact of long COVID during the 2021-2022 Omicron wave in Australia: a quantitative burden of disease study

Authors

Samantha Howe*[#]

Dr Joshua Szanyi[#]

Professor Tony Blakely[#]

[#]Population Interventions Unit, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Carlton, VIC, 3053

*Corresponding author: 207 Bouverie Street, Carlton, VIC, 3053.

slhowe@student.unimelb.edu.au

Word count: 3755

Abstract

Background

Long COVID symptoms occur for a proportion of acute COVID-19 survivors, with reduced risk among the vaccinated, and for Omicron compared to Delta variant infections. The health loss attributed to pre-Omicron long COVID has previously been estimated using only a few major symptoms.

Methods

The years lived with disability (YLDs) due to long COVID in Australia during the 2021-2022 Omicron BA.1/BA.2 wave were calculated using inputs from previously published case-control, cross-sectional, or cohort studies examining the prevalence and duration of individual long COVID symptoms. This estimated health loss was compared with acute SARS-CoV-2 infection YLDs and years of life lost (YLLs) from SARS-CoV-2. The sum of these three components equals COVID-19 disability-adjusted life years (DALYs); this was compared to DALYs from other diseases.

Results

5200 (95% uncertainty interval [UI] 2200-8300) YLDs were attributable to long COVID and 1800 (95% UI 1100-2600) to acute SARS-CoV-2 infection, suggesting long COVID caused 74% of the overall YLDs from SARS-CoV-2 infections in the BA.1/BA.2 wave. Total DALYs attributable to SARS-CoV-2 were 50 900 (95% UI 21 000-80 900), 2.4% of expected DALYs for all diseases in the same period.

Conclusion

This study provides a comprehensive approach to estimating the morbidity due to long

COVID. Improved data on long COVID symptoms will improve the accuracy of these

estimates. As data accumulates on SARS-CoV-2 infection sequelae (e.g., increased

cardiovascular disease rates), total health loss is likely to be higher than estimated in this

study. Nevertheless, this study demonstrates that long COVID requires consideration in

pandemic policy planning given it is responsible for the majority of direct SARS-CoV-2

morbidity, including during an Omicron wave in a highly vaccinated population.

Key messages

- Our study is the first to comprehensively estimate long COVID morbidity using its

individual symptoms, during Australia's 2021-2022 Omicron wave.

- We show that long COVID contributed to almost three-quarters of the non-fatal

health loss resulting from Omicron infections in this period.

- Long COVID contributes to a substantial proportion of direct COVID-19 morbidity,

even in a highly vaccinated population during an Omicron wave. It should therefore

be more explicitly considered in future pandemic policymaking.

- Our method of estimating long COVID morbidity has explicable differences to

existing long COVID burden of disease approaches and may provide a more accurate

estimate of the morbidity attributable to long COVID.

Introduction

A post-acute phase of SARS-CoV-2 infection, commonly termed long COVID, occurs among some individuals following acute infection. Long COVID describes the persistence and/or emergence of a heterogeneous group of symptoms at least 12 weeks after acute infection.[1] There is no current consensus on the symptom profile that specifically characterises long COVID, with a wide range of symptoms being reported across multiple organ systems, including cardiopulmonary, neurological, and musculoskeletal systems.[2] While some studies report symptom clustering within individuals, the frequency and significance of this remains unclear and individuals most commonly report experiencing one or two symptoms.[3,4] The aetiology of long COVID is proposed to be related to continued immune activation and persistence of the virus in the various organ systems infected during the acute period.[5] Numerous risk factors have been identified, including a propensity towards an autoimmune response, female sex, co-morbidities such as Type 2 Diabetes Mellitus, and a more severe acute infection.[4,6] Importantly, COVID-19 vaccination has been found to reduce the risk of long COVID.[7,8]

Given ongoing high rates of SARS-CoV-2 transmission globally, it is important to quantify the full health impact of SARS-CoV-2 infection, including its longer-term consequences. Recent burden of disease studies have quantified long COVID by treating it as a single outcome, utilising the Global Burden of Disease (GBD) study health state of 'post-acute consequences' from other respiratory illnesses, or chronic fatigue syndrome, to approximate long COVID severity.[9-11] While these health states have some overlap with documented long COVID symptoms, they do not acknowledge the full breadth of symptoms linked to long COVID, or the heterogeneity of symptoms reported between individuals.[2,9]

A lack of high-quality evidence regarding the prevalence and duration of symptoms hampers

quantification of long COVID burden. Many studies of long COVID lack an appropriate

control group or are subject to other methodological issues. Of particular concern is selection

bias from self-selection into studies by those experiencing ongoing symptoms and loss-to-

follow up by those no longer symptomatic. These biases likely inflate estimates of long

COVID occurrence. Conversely, studies with insufficient follow-up time may not capture

the full burden of long COVID symptoms, which are often relapsing and remitting in nature.[2]

In addition to these design issues, the majority of published long COVID research has been

conducted in cohorts of unvaccinated, pre-Omicron variant infected cases. To accurately

quantify the impact of long COVID in highly vaccinated populations during Omicron waves,

differences in the risk of long COVID by vaccination and variant need incorporating.

This paper addressed the following research questions: firstly, what is the extent of the

morbidity attributable to long COVID resulting from Omicron variant SARS-CoV-2

infections, quantified 'bottom-up' from occurrence rates of each symptom and its severity

and duration? Secondly, what proportion of total years lived with disability (YLDs) and

disability-adjusted life years (DALYs) accumulated during the 2021-2022 Omicron wave in

Australia were due to long COVID, and how does this health loss compare to other major

causes of health loss in Australia?

Methods

Morbidity calculations

In this study, the impact of long COVID in the Australian population is measured with a

burden of disease approach. Disability-Adjusted Life Years are a standard metric of disease

burden and encompass both morbidity (as YLDs), and mortality (as years of life lost [YLL]).

YLDs are the focus of this paper, as long COVID is treated as a collection of non-fatal

symptoms; however overall DALYs combining both acute and long COVID are also

measured.

Long COVID morbidity was calculated as that expected per symptomatic SARS-CoV-2

infected person:

$$Expected\ Long\ COVID\ morbidity\ per\ symptomatic\ survivor$$

$$= \sum_i (Prevalence_{i\ only}\ \times\ Duration_i\ \times Severity_i)$$

$$+ \sum_i \sum_{j=i+1} (Prevalence_i\ \times Prevalence_j\ \times\ Min\ [Duration_{i\ or\ j}]$$

$$\times Severity_{i\ and\ j})$$

where i and j index each possible symptom, and $Prevalence_{i\ only}$ is the prevalence of

symptom i minus the sum of the joint occurrence of symptom i with each other symptom

(assuming symptom occurrence is independent). The prevalence of each symptom was

calculated as a risk difference in symptom frequency between SARS-CoV-2 survivors and

SARS-CoV-2-negative controls, extracted from previous research (see Supplementary Table

1 and Supplementary Table 2, available as Supplementary data at *IJE* Online).[3,12-14] Only

symptoms found to occur more frequently in COVID-19 cases compared to COVID-negative

controls, in the controlled literature, were included (presented in Table 1). The severity of

each symptom was quantified as a disability weight (DW) taken from the GBD study [15] for

the matching health state, and best matches otherwise (e.g. DWs of other sensory conditions

have been used as proxies for dysosmia and dysgeusia). $Severity_{i\ and\ j}$ was calculated as [16]:

$$1 - (1 - DW_i) \times (1 - DW_j)$$

It was assumed that only initially symptomatic patients (during the acute illness period) are at

risk of long COVID – the risk of long COVID among asymptomatic patients has been found

to be low or nil compared to symptomatic patients. [17-19] We also assumed that calculations

including all three-way (or higher) combinations of symptoms would make negligible

difference to morbidity estimates – given that most symptom prevalence estimates are less

than 10% (Table 1), and joint prevalence calculations are multiplicative, the joint prevalence

of three or more symptoms using this method would be very low. Additionally, it is

uncommon to experience more than two symptoms).[12]

The above 'base case' prevalence calculations were for unvaccinated individuals infected

with a pre-Omicron variant of SARS-CoV-2, and were split into three sub-groups: adult

community cases, adult hospitalised cases, and children (0-17 years, any acute disease

severity).[3,12-14] Long COVID symptom prevalence among previously hospitalised adults is

approximately twice that among community cases.[12] Symptom prevalence is also lower

among children compared to adults.[14] Duration of each symptom (from one week post-

infection for mild/moderate cases, and approximately 2.5 weeks post-infection for those

hospitalised) was applied based on recent findings by Wulf Hansen et al., who reported a

median duration of symptoms for community infections of four months, and 8.9 months for

previously hospitalised cases.[20] Exceptions to this have been applied to psychological

symptoms, for which a shorter duration was used, and similarly for children (see Table 1).[13,21]

These base case prevalences were then multiplied by an odds ratio (OR) of 0.55 to

approximate symptom prevalence among vaccinated cases based on findings from two

studies that found reduced odds of symptoms following the acute infection by 49% and 41%,

for those who had at least two COVID-19 vaccines compared to one/no vaccines.[7,8]

Vaccination post-infection has been found to have a limited effect on long COVID

occurrence – therefore, only vaccination prior to infection was considered.[22,23] Next,

prevalence estimates were further multiplied by an OR of 0.25 based on an estimate of the

reduction in prevalence of any symptoms at least four weeks post-infection for Omicron

variant compared to Delta variant infections in a vaccinated cohort in the United Kingdom.[24]

It was assumed that this association remains beyond 12 weeks post-infection. The exception

to the latter multiplier was adults hospitalised with an Omicron infection (the previously

mentioned study was conducted using a cohort of primarily community cases); we assumed

that once a case is severe enough to be hospitalised, there is no difference in resulting long

COVID compared to pre-Omicron variants. A flow diagram depicting the above method to

cross walk prevalence data from pre-Omicron, unvaccinated cases to Omicron, vaccinated

cases is presented in Figure 1.

Uncertainty was included using a standard deviation (SD) of +/- 20%, applied to base case

long COVID morbidity estimates. This method approximated the 95% uncertainty in base

case estimates achieved using a more comprehensive approach, where variance in duration,

severity and prevalence were each calculated to estimate total variance. For morbidity

calculations for vaccinated and Omicron-infected populations, we used a SD of +/- 30% of

the expected value to reflect additional uncertainty.

The DW, estimated prevalence, and average duration of each identified long COVID

symptom among Omicron infected, unvaccinated cases, along with the uncertainty applied,

are presented in Table 1. The prevalence among vaccinated cases is that shown in Table 1

multiplied by 0.55. The estimated prevalence and duration of each symptom among base

cases (i.e., unvaccinated, pre-Omicron infections) is presented in Supplementary Table 3,

available as Supplementary data at *IJE* online.

Application to the Omicron wave and health burden comparison

Long COVID YLDs were calculated as the expected long COVID morbidity per

symptomatic case multiplied by the total number of symptomatic infections (treated as

equivalent to notified cases) during the four months of the Omicron BA.1/BA.2 wave in

Australia, defined here as December 10th 2021 to April 9th 2022.

The YLDs from acute SARS-CoV-2 infection were estimated based on a previously

published method by Blakely et al. [25], updated here to be specific to Omicron-variant

infections. Acute COVID-19 morbidity is sub-divided into community cases and hospitalised

cases that are either ward only or include an ICU admission – approximately 8% of cases in

hospital have been estimated as requiring ICU admission during the first four months of the

Omicron wave.[26] Symptom duration estimates for hospitalised patients were based on

findings from a New South Wales (NSW) study by Tobin et al.[27], which estimated hospital

stay duration during December (at the start of the Omicron wave). These duration estimates

were weighted across the three age categories presented by Tobin et al.[27] (0-39 year olds, 40-

69 year olds and 70+ year olds) based on the proportion hospitalised in each age group. A

percentage split of 72% mild and 28% moderate acute illness for non-hospitalised cases was

based on findings by Menni et al. [28], which indicated that the odds of moderate severity

illness was reduced by approximately 44% for Omicron compared to Delta infections.

Previous estimates used by Blakely et al.[25] for pre-Omicron variant infections utilised a 50/50

split for the proportions of moderate vs. mild community cases. Acute COVID-19 morbidity

inputs are presented in Supplementary Table 4, available as Supplementary data at *IJE*

online.

YLLs due to SARS-CoV-2 deaths were estimated using standard burden of disease methods

[29], multiplying reported deaths due to COVID-19 with the average remaining life expectancy

of those who died (with reference life expectancy by sex and age obtained from the 2019

GBD, retrieved from the Institute for Health Metrics and Evaluation [IHME] results tool).[30,31]

YLL and YLD calculations were by strata of age (<18-year-olds vs. ≥18-year-olds),

hospitalisation status (as described above) and vaccination – national level data was not

available at the time of writing for vaccination status of COVID-19 cases, therefore data from

NSW was applied.[32]

The total DALYs from SARS-CoV-2 infection in these four months were calculated as the

sum of the above three components. For the purposes of this paper, we assigned the long

COVID YLDs to the SARS-CoV-2 infections occurring in the four-month window.

For comparison, we took the YLDs and DALYs in Australia for other diseases from GBD

2019 (adjusted to reflect the 2021 population [mid-year])[31,33], dividing by three to make them

equivalent to the four-month duration of the BA.1/BA.2 wave.

Sensitivity analyses

One-way sensitivity analyses were conducted on base case morbidity estimates, separately

varying the prevalence, severity and duration components by their 95% uncertainty intervals

(UI). Additionally, each base case estimate was varied for the adult cohorts by the symptoms

extracted from different source studies. This included varying the prevalence, duration and

severity components together by their respective 95% UI, separately for: physical symptoms

obtained from Sørensen et al.[12]; psychological symptoms from Caspersen et al.[3]; and

cognitive symptoms from Magnúsdóttir et al.[13]).

An extreme scenario analysis was also conducted in which the OR for Omicron compared to

pre-Omicron infections (OR=0.25) was applied to the hospitalised patient group, as applied

for community cases only in the main analysis.

<u>Results</u>

Some 4.87 million COVID-19 cases were notified in Australia during the first four months of

the Omicron wave, with approximately 35 500 hospitalisations and 3463 deaths. [26,30,34,35]

An estimated 61% of notified cases were vaccinated at the time of infection (noting that

approximately 90% of 16+ year olds in the population were fully vaccinated by 10 December

2021).[32,36] Reported cases and deaths are shown in Supplementary Table 5 and

Supplementary Table 6, available as Supplementary data at *IJE* online.

The overall morbidity (i.e. YLDs) resulting from infections in this period, including acute

and long COVID is shown in Figure 2 (with YLDs by sub-group presented numerically in

Table 2). Long COVID accounted for approximately 74% of the overall non-fatal COVID-19

health loss among notified cases during the first 4 months of the Australian Omicron wave, at

5200 YLDs (95% uncertainty interval [UI] 2200-8300). The majority of long COVID YLDs

come from community cases, with the highest number in the vaccinated community adult

cases sub-strata (2100 YLDs, 95% UI 900-3500) given that this group represents the greatest

proportion of notified cases (Supplementary Table 5, available as Supplementary data at *IJE*

online). Per person COVID morbidity estimates, which show the non-fatal health loss due to

long COVID per notified COVID-19 case are shown for each sub-group in Supplementary

Table 7, available as Supplementary data at *IJE* online.

The overall DALYs resulting from reported COVID-19 infections in the four-month period

was estimated at 50 900 (95% UI 21 000-80 900), of which long COVID contributed 10.3%

(compared to the acute COVID-19 morbidity contribution of 3.6%). The remaining DALYs

resulted from acute COVID-19 mortality.

The leading 25 causes of morbidity in Australia ranked by YLDs are presented in Figure 3A

along with the estimated YLDs resulting from reported COVID-19 cases during the first four

months of the Omicron wave. Total COVID-19 morbidity is ranked 24th, comparable to the

non-fatal health loss resulting from chronic kidney disease.

The leading 25 causes of health loss in Australia ranked by DALYs, are presented in Figure

3B along with the estimated DALYs resulting from the first four months of the COVID-19

Omicron wave. The DALYs resulting from COVID-19 cases are estimated to be 2.4% of all

expected DALY loss in the four months, and rank 10th among conditions (between

Alzheimer's and other dementias, and drug use disorders). The 95% UI indicates that the

rank could in fact be as high as 3rd (between low back pain and falls) or as low as 24th (below

alcohol use disorders).

Discussion

We estimated that long COVID contributed to approximately 74% of the non-fatal health loss

(i.e., YLDs) resulting from reported COVID-19 infections in the first four months of the

Omicron BA.1/BA.2 wave in Australia. Given that morbidity was calculated using notified

cases, and some unreported cases will have been symptomatic, this may be an underestimate.

The total YLDs for acute and long COVID combined were estimated as comparable to YLDs

caused by chronic kidney disease and ischaemic heart disease (Figure 3A). The overall

COVID-19 disease burden, YLDs plus years of life lost, was estimated at 50 900 DALYs

(95% UI 21 000-80 900) over the initial four months of the Omicron wave, the 10th highest

cause of DALYs in this four-month period in Australia and approximately 2.4% of all health

loss (Figure 3B).

Our per person morbidity estimates for long COVID show that for a vaccinated adult case

who did not require hospitalisation during their acute infection (i.e. the majority of cases in

the first four months of the Omicron wave in Australia), 0.09% of a healthy year of life is lost

due to long COVID (equivalent to one third of a day of healthy life lost). It is important to

note that the morbidity loss for someone actually with long COVID would be much greater

than this, as this estimate (and those shown in Supplementary Table 7, available as

Supplementary data at *IJE* online) gives the health loss for any surviving notified COVID-19

case.

A strength of our study is allowing for the lower incidence of long COVID among vaccinated

people, and with Omicron versus pre-Omicron variants; to our knowledge, previous studies

have not made both allowances. Our approach also quantifies long COVID morbidity across

multiple patient sub-groups and includes a complete symptom profile rather than treating

long COVID as a single outcome.

A recent study by Wulf Hanson et al. and Institute for Health Metrics and Evaluation (IHME)

collaborators estimated the proportion of SARS-CoV-2 infections developing long COVID,

separated into three symptom groups, for SARS-CoV-2 infections in 2020 and 2021.[20] Their

method involved measuring the prevalence of each symptom individually as well as the

prevalence of each symptom pair and all three symptoms together. Using this method, then

applying odds ratios for long COVID for Omicron compared to pre-Omicron, and

vaccination status, our morbidity estimate observing the equivalent symptom groups is within

20% of the resulting estimate from the IHME method (as shown in Supplementary Table 8,

available as Supplementary data at *IJE* online).[20] This indicates that our assumption of

independence is valid for burden estimation of long COVID.

Our approach does not provide an overall estimate of long COVID occurrence rate, given that

we define long COVID as a heterogeneous group of symptoms, rather than a single outcome.

The utility in our approach is in the use of severity and duration estimates specific to each

symptom, to more accurately estimate the morbidity attributed to long COVID in a

population. The use of single health states, such as 'post-acute consequences' (as currently

recommended by the European Burden of Disease Network)[37] assumes that the average long

COVID sufferer has all these symptoms included within the applied health state. It also

ignores a large proportion of symptoms that have been identified among long COVID

sufferers. In Supplementary Table 9 (available as Supplementary data at *IJE* online), we

compare our morbidity estimate with those from other COVID-19 burden of disease studies

that have incorporated long COVID. Long COVID parameters published by the Australian

Institute of Health and Welfare (AIHW) [10], and adjusted by us to reflect vaccinated, Omicron

infections, result in an estimate approximately two-thirds of our finding, likely due to the

reduced duration applied (91 days) and the use of a single health state (post-acute

consequences; DW=0.219). Three other non-Australian publications, which applied an even

shorter duration of 28 days, with a single long COVID health state, produced estimates

approximately one-third of our morbidity estimate.[38-40] These differences highlight the

strength of our paper, which accounts for a wider range of long COVID symptoms, and a

longer average duration of symptoms reflecting that documented in the existing literature.

Our approach also accounts for the difference in risk of long COVID symptoms by acute

COVID-19 severity, and age, which these publications have not considered. We postulate

that our 'bottom up' approach provides a more accurate measure of morbidity resulting from

long COVID.

Our study has limitations. Long COVID is an area of rapidly emerging and evolving

research, currently characterised by limited high-quality literature. As such, there is a high

level of uncertainty in our findings (e.g., our 'cross-walk' of pre-Omicron unvaccinated data

to Omicron vaccinated cases). Additionally, while the studies utilised for our prevalence

estimates were included based on an assessment of bias and methodological quality,

prevalence may still be overestimated, due to the likely direction of bias to over-estimation in

long COVID studies. A recently published prospective cohort study that controlled for

symptoms present prior to COVID-19 diagnosis, found a slightly reduced occurrence of

symptoms among COVID-positive cases compared to controls than our base case analysis.[41]

While these estimates were not able to be used in this paper, given that the study did not

stratify data by age and severity of acute infection, as more data becomes available on the

prevalence of symptoms among strata Omicron-infected cases our estimates can be updated.

Further stratification of patient groups may also help to improve the accuracy of our current

framework, for example by increasing the number of age strata and including sex. There is an

increased risk of long COVID among older age groups and females [42], however, data on

symptom prevalence was not available allow for this in our analysis in addition to the

variables we included.

Given the lack of data on the occurrence of long COVID symptoms among previously

hospitalised Omicron cases, and the known association between acute COVID-19 severity

and long COVID risk,[12] we assumed no difference in long COVID morbidity between the

hospitalised base case group (i.e. pre-Omicron infections) and Omicron hospitalised cases. In

a sensitivity analysis, we tested an 'extreme' for this sub-group, applying the odds ratio

(OR=0.25) used for cross walking of community pre-Omicron to community Omicron cases,

to the hospitalised group.[24] While this reduced the morbidity for the hospitalised patient

group by an average of 81.5% compared to the main analysis, overall long COVID morbidity

was only reduced by 12% compared to the main analysis, to 4600 YLDs (95% UI 1900-

7200) (see Supplementary Table 10, available as Supplementary data at *IJE* online). This

estimate largely overlaps with that from our primary analysis, however, it will still be

important to conduct further research into long COVID among hospitalised Omicron cases in

the future, including consideration of those requiring ICU treatment vs. ward treatment only

(which was not possible in this study given a lack of data available).

Additional one-way sensitivity analyses, presented as Tornado plots, showed that the

majority of the overall uncertainty in long COVID morbidity in our study was due to

uncertainty in the morbidity severity estimates for symptoms (i.e. disability weights), as

opposed to uncertainty in symptom frequency and duration (Supplementary Figure 1,

available as Supplementary data at *IJE* online). This is of concern, given that the majority of

DWs applied were made by estimation from other health states [15], and points to the need for

research to better quantify the severity of each long COVID symptom.

It is important to note that many people dying of COVID-19 have co-morbidities, so their

true YLLs will be less than that measured using standard DALY methods, which assumes

those dying of COVID-19 have the mortality rate specified in the reference life table. It is

also important to note that our study focuses on health loss from acute and long COVID;

SARS-CoV-2 infection has also been associated with persistent organ damage, and an

increased risk of chronic conditions including Type 2 Diabetes Mellitus and cardiovascular

disease, particularly among those who had a severe acute infection.[43-47] Longer-term research

will be required in the future to determine the extent that SARS-CoV-2 infection causes these

sequelae, which will lead to the total burden of SARS-CoV-2 being (perhaps considerably)

greater than that quantified in this study.

<u>Conclusion</u>

Our approach for estimating the morbidity attributable to long COVID likely provides a more

accurate measure of long COVID burden compared to that of existing burden of disease

studies. Whilst the prevalence of long COVID symptoms is less now among highly

vaccinated populations with Omicron than it was for pre-Omicron variants among

unvaccinated populations, long COVID still contributes substantial health loss when summed

over all infections. Our findings therefore highlight the need to factor in long COVID-related

health loss when making policy decisions.

Ethical approval

This study did not require ethical approval.

Author contributions

Conceptualisation: S.H., J.S., T.B. Literature review: S.H. Formal analysis: S.H., T.B.

Writing – original draft: S.H., J.S., T.B. Writing – review & editing: S.H., J.S., T.B.

Data availability

The data underlying this article will be shared on reasonable request to the

corresponding author

Supplementary data

Supplementary data are available at *IJE* online.

Funding

None.

Acknowledgements

Expert knowledge was kindly provided by Professor John D. Potter (Massey

University, Wellington, Fred Hutchinson Cancer Research Centre, Seattle,

Washington and University of Washington, Seattle, Washington).

Conflict of interest

The Population Interventions Unit is expected to receive funding from Moderna Inc. to conduct research on COVID-19 vaccine effectiveness in Victoria, Australia. No other conflicts of interest are declared.

References

1. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-COVID-19 condition by a Delphi consensus. *Lancet Infect Dis*. 2022;**22**(4):e102-e7.

2. Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'em Y, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. *EClinicalMedicine*. 2021;**38**:101019.

3. Caspersen IH, Magnus P, Trogstad L. Excess risk and clusters of symptoms after COVID-19 in a large Norwegian cohort. *Eur J Epidemiol*. 2022;**37**(5):539-548.

4. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. *Nature Medicine*. 2021;**27**(4):626-31.

5. Akbarialiabad H, Taghrir MH, Abdollahi A, Ghahramani N, Kumar M, Paydar S, et al. Long COVID, a comprehensive systematic scoping review. *Infection*. 2021;**49**(6):1163-86.

6. Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. *Cell*. 2022;**185**(5):881-95.e20.

7. Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E, Berry S, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. *Lancet Infect Dis*. 2022;**22**(1):43-55.

8. Office for National Statistics (ONS). Self-reported long COVID after two doses of a coronavirus (COVID-19) vaccine in the UK: 26 January 2022. ONS. 2022. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/con

ditionsanddiseases/bulletins/selfreportedlongcovidaftertwodosesofacoronaviruscovid19vaccineintheuk/26january2022. (26 Jan 2022, dated last accessed).

9. Smith MP. Estimating total morbidity burden of COVID-19: relative importance of death and disability. *J Clin Epidemiol*. 2022;**142**:54-9.

10. Australian Institute of Health and Welfare (AIHW). The first year of COVID-19 in Australia: direct and indirect health effects. Canberra, ACT: AIHW; 2021.

11. Angeles MR, Wanni Arachchige Dona S, Nguyen HD, Le LK, Hensher M. Modelling the potential acute and post-acute burden of COVID-19 under the Australian border re-opening plan. *BMC Public Health*. 2022;**22**(1):757.

12. Sørensen AIV, Spiliopoulos L, Bager P, Nielsen NM, Hansen JV, Koch A, et al. Post-acute symptoms, new onset diagnoses and health problems 6 to 12 months after SARS-CoV-2 infection: a nationwide questionnaire study in the adult Danish population. *Nat. Commun*. 2022;**13**(4213).

13. Magnúsdóttir I, Lovik A, Unnarsdóttir AB, McCartney D, Ask H, Kõiv K, et al. Acute COVID-19 severity and mental health morbidity trajectories in patient populations of six nations: an observational study. *Lancet Public Health*. 2022;**7**(6):E406-E416.

14. Behnood SA, Shafran R, Bennett SD, Zhang AXD, O'Mahoney LL, Stephenson TJ, et al. Persistent symptoms following SARS-CoV-2 infection amongst children and young people: A meta-analysis of controlled and uncontrolled studies. *J Infect*. 2022;**84**(2):158-70.

15. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet*. 2020;**396**(10258):1204-22.

16. van Baal PHM, Hoeymans N, Hoogenveen RT, de Wit AG, Westert GP. Disability weights for comorbidity and their influence on Health-adjusted Life Expectancy. *PHM*. 2006;**4**(1):1.

17. Strahm C, Seneghini M, Güsewell S, Egger T, Leal O, Brucher A, et al. Symptoms compatible with long-COVID in healthcare workers with and without SARS-CoV-2 infection - results of a prospective multicenter cohort. *Clin Infect Dis*. 2022;**75**(1):e1011-e1019.

18. Adler L, Gazit S, Pinto Y, Perez G, Mizrahi Reuveni M, Yehoshua I et al. Long-COVID in patients with a history of mild or asymptomatic SARS-CoV-2 infection: a Nationwide Cohort Study. *Scand J Prim Health Care*. 2022:1-8.

19. Hastie CE, Lowe DJ, McAuley A, Winter AJ, Mills NL, Black C, Scott JT, O'Donnell CA, Blane DN, Browne S, Ibbotson TR, Pell JP. Outcomes among confirmed cases and a matched comparison group in the Long-COVID in Scotland study. Nat Commun. 2022 Oct 12;13(1):5663. doi: 10.1038/s41467-022-33415-5. Erratum in: Nat Commun. 2022 Nov 1;13(1):6540. PMID: 36224173; PMCID: PMC9556711.

20. Wulf Hanson S, Abbafati C, Aerts JG, Al-Aly Z, Ashbaugh C, Ballouz T et al. Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021. *JAMA*. 2022;**328**(16):1604-1615.

21. Borch L, Holm M, Knudsen M, Ellermann-Eriksen S, Hagstroem S. Long COVID symptoms and duration in SARS-CoV-2 positive children — a nationwide cohort study. *EJPE.* 2022.**181**(4):159-1607.

22. Ayoubkhani D, Bermingham C, Pouwels KB, Glickman M, Nafilyan V, Zaccardi F, et al. Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study. *BMJ*. 2022;**377**:e069676.

23. Wisnivesky JP, Govindarajulu U, Bagiella E, Goswami R, Kale M, Campbell KN, et al. Association of Vaccination with the Persistence of Post-COVID Symptoms. *J Gen Intern Med*. 2022;**37**(7):1748-53.

24. Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. *Lancet*. 2022;**399**(10343):2263-4.

25. Blakely T, Thompson J, Bablani L, Andersen P, Ait Ouakrim D, Carvalho N, et al. Association of Simulated COVID-19 Policy Responses for Social Restrictions and Lockdowns With Health-Adjusted Life-Years and Costs in Victoria, Australia. *JAMA Health Forum*. 2021;**2**(7):e211749-e.

26. COVID Live. Hospitalisations: current cases admitted to hospital. 2022. https://covidlive.com.au/report/hospitalised. (1 June 2022, date last accessed).

27. Tobin RJ, Wood JG, Jayasundara D, Sara G, Walker J, Martin GE, et al. Hospital length of stay in a mixed Omicron and Delta epidemic in New South Wales, Australia. medRxiv. doi:10.1101/2022.03.16.22271361. 19 March 2022. preprint: not peer reviewd.

28. Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S, Nogal A, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. *Lancet*. 2022;**399**(10335):1618-1624.

29. Australian Institute of Health and Welfare (AIHW). Australian Burden of Disease Study: Impact and causes of illness and death in Australia 2018. Canberra: AIHW; 2021.

30. COVID-19 National Incident Room Surveillance Team. COVID-19 Australia: Epidemiology Report 60: Reporting period ending 10 April 2022. *Commun Dis Intell (2018).* 2022;**46**.

31. Institute for Health Metrics and Evaluation (IHME). GBD results. 2022. https://vizhub.healthdata.org/gbd-results/. (2 June 2022, date last accessed).

32. New South Wales Ministry of Health. COVID-19 weekly surveillance reports – archive. 2022. https://www.health.nsw.gov.au/Infectious/covid-19/Pages/weekly-reports-archive.aspx. (1 June 2022, date last accessed).

33. Australian Bureau of Statistics (ABS). National, state and territory population. 2022. https://www.abs.gov.au/statistics/people/population/national-state-and-territory-population/latest-release. (14 Nov 2022, date last accessed).

34. COVID Live. New Cases: total cases and new last 24hrs. 2022. https://covidlive.com.au/report/cases. (1 June 2022, date last accessed).

35. Ting I, Workman M, Shatoba K, Hutcheon S, Palmer A. Australian Broadcasting Corporation. Charting the spread of COVID-19 in Australia. 2020 [updated 2022 May 25]. https://www.abc.net.au/news/2020-03-17/coronavirus-cases-data-reveals-how-covid-19-spreads-in-australia/12060704-newcases. (1 June 2022, date last accessed).

36. Department of Health and Aged Care, Commonwealth of Australia. COVID-19 vaccine rollout – 10 December 2021. 2021. https://www.health.gov.au/resources/publications/covid-19-vaccine-rollout-update-10-december-2021. (18 Nov 2022, date last accessed).

37. European Burden of Diseae Network (EBoDN). Burden of disease of COVID-19: protocol for country studies. 2022. https://www.burden-eu.net/docs/covid19-bod-protocol.pdf. (27 September 2022, date last accessed).

38. Wyper GMA, Fletcher E, Grant I, McCartney G, Fischbacher C, Harding O, Jones H, de Haro Moro MT, Speybroeck N, Devleesschauwer B, Stockton DL. Measuring disability-adjusted life years (DALYs) due to COVID-19 in Scotland, 2020. *Arch Public Health*. 2022 Apr 1;**80**(1):105.

39. Cuschieri S, Calleja N, Devleesschauwer B, Wyper GMA. Estimating the direct Covid-19 disability-adjusted life years impact on the Malta population for the first full year. *BMC Public Health*. 2021:**21**(1827).

40. Moran DP, Pires SM, Wyper GMA, Devleesschauwer B, Cuschieri S, Kabir Z. Estimating the Direct Disability-Adjusted Life Years Associated With SARS-CoV-2 (COVID-19) in the Republic of Ireland: The First Full Year. *Int J Public Health*. 2022 Jun 2;**67**:1604699.

41. Ballering AV, van Zon SKR, Hartman TC, Rosmalen JGM. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. *Lancet*. 2022;**400**(10350):452-461.

42. Whitaker M, Elliott J, Chadeau-Hyam M, Riley S, Darzi A, Cooke G, Ward H, Elliott P. Persistent COVID-19 symptoms in a community study of 606,434 people in England. *Nat Commun*. 2022;**13**(1):1957.

43. Ayoubkhani D, Khunti K, Nafilyan V, Maddox T, Humberstone B, Diamond I, et al. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. *BMJ*. 2021;**372**:n693.

44. Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. *Nat. Med*. 2022;**28**:583-590.

45. Douaud G, Lee S, Alfaro-Almagro F, Arthofer C, Wang C, McCarthy P, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. *Nature*. 2022;**604**:697-707.

46. Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, et al. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol*. 2020;**5**(11):1265-73.

47. Dennis A, Wamil M, Alberts J, Oben J, Cuthbertson DJ, Wootton D, et al. Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study. *BMJ Open*. 2021;**11**(3):e048391.

Sequelae	DW (95% CI)	Health state/justification	Prevalence among Omicron cases (unvaccinated) [a]		Duration (months) [b]	
Adults			Community	Hospitalised [c]	Community	Hospitalised [c]
Dysosmia	0.01 (0.004-0.020)	Health state: hearing loss, mild & presbyopia. Assumed to be equivalent to mild impairment of other senses.	2.6%	7.0%	4 months	9 months
Dysgeusia	0.01 (0.004-0.020)	Health state: hearing loss, mild & presbyopia Assumed to be equivalent to mild impairment of other senses.	2.1%	6.9%	4 months	9 months
Fatigue	0.051 (0.036-0.062) [d]	Health state: infectious disease, post-acute consequences (adjusted down for depression and pain). No reasonable estimate exists for fatigue in GBD study 2019, however reasonable estimates exist for muscle/joint pain, and depression. Therefore, DW applied in the present study for depression and muscle/joint pain were subtracted from 'post-acute consequences' DW (DW=0.219 [95% CI 0.148-0.308]), which is characterised by weakness/tiredness, depression and body pain.	2.0%	13.1%	4 months	9 months
Dyspnoea	0.019 (0.011-0.033)	Health state: chronic obstructive pulmonary disease (COPD) and other chronic respiratory problems, mild.	1.1%	10.3%	4 months	9 months
Chest pain	0.011 (0.005-0.021)	Health state: abdominopelvic problem, mild. Assumed to be equivalent to gastroesophageal reflux disease (GERD).	0.5%	4.1%	4 months	9 months
Muscle weakness	0.004 (0.001-0.008)	Health state: anaemia, mild. Mild anaemia characterised by feeling slightly weak/tired.	1.0%	11.3%	4 months	9 months
Dizziness	0.032 (0.021-0.046) [d]	Health state: vertigo (adjusted to estimate 'mild' vertigo health state). Assumed that dizziness is mild form of vertigo – as there is no 'mild' vertigo DW, 'vertigo' DW (DW=0.113 [95% CI: 0.074-0.158]) was multiplied by 0.29 (average ratio of mild/moderate DWs across all	0.6%	4.8%	4 months	9 months

		outcomes with mild, moderate, and severe ratings in the GBD study 2019).				
Muscle/joint pain	0.023 (0.013-0.037)	Health state: musculoskeletal problems, lower limbs, mild.	0.8%	6.3%	4 months	9 months
Headache	0.037 (0.022-0.057)	Health state: headache, tension-type.	0.8%	4.3%	4 months	9 months
Numb/tingling limbs	0.023 (0.013-0.037)	Health state: musculoskeletal problems, lower limbs, mild.	0.8%	7.0%	4 months	9 months
Concentration difficulty [e]	0.069 (0.046-0.099)	Health state: dementia, mild.	1.9%	10.9%	4 months	9 months
Memory impairment [e]	0.069 (0.046-0.099)	Health state: dementia, mild.	1.4%	14.3%	4 months	9 months
Insomnia	0.03 (0.018-0.046)	Health state: anxiety disorder, mild. Anxiety disorder is characterised by difficulty sleeping and concentrating.	1.3%	19.4%	3 months	3 months
Anxiety	0.03 (0.018-0.046)	Health state: anxiety disorder, mild.	N/A	11.8%	N/A	3 months
Depression	0.145 (0.099-0.209)	Health state: major depressive disorder, mild.	N/A	23.2%	N/A	3 months
Children [f]						
Dysosmia	0.01 (0.004-0.020)	Health state: hearing loss, mild & presbyopia. Assumed to be equivalent to mild impairment of other senses.	2.0%		3 months	
Headache	0.037	Health state: headache, tension-type.	1.3%		3 months	

	(0.022-0.057)			
Eye soreness	0.011 (0.005-0.02)	Health state: presbyopia. No health states eye pain exist in GBD study 2019, therefore estimated from presbyopia (characterised by mild near vision loss).	0.5%	3 months
Sore throat	0.006 (0.002-0.012)	Health state: infectious disease, acute episode, mild. Assumed to be equivalent to mild upper respiratory infection.	0.5%	3 months
Cognitive difficulty	0.045 (0.028-0.066)	Health state: attention deficit hyperactivity disorder (ADHD). ADHD is characterised by difficulty with concentration and memory.	0.8%	3 months

[a] Multiply by 0.55 (on odds scale) to obtain prevalence among vaccinated.
[b] Duration applied excludes acute morbidity period (one week for mild [non-hospitalised] adult cases and children, or 2.6 weeks for hospitalised adult cases – see Supplementary Table 4 for acute COVID-19 morbidity details).
[c] Symptom prevalence among initially hospitalised COVID-19 cases does not differ between pre-Omicron and Omicron variants, as outlined in the Methods.
[d] DW applied is not directly taken from a DW in the 2019 GBD, instead estimated by adjusting existing DWs.
[e] Community and hospitalised sub-groups for cognitive symptoms are achieved through weighting of estimates from mild vs. severe sub-groups as measured by Caspersen et al.[6]
[f] Children are not separated by severity of acute infection.
Health states applied were obtained from the 2019 GBD study.[15]
CI = Confidence Interval; DW = Disability Weight; GBD = Global Burden of Disease.

Figure 1: Flow diagram – prevalence crosswalk method

OR=0.25 indicates reduced odds of long COVID among Omicron-infected cases compared to Delta-infections - applied to not hospitalised (i.e., community) adult cases and children.

OR=0.55 indicates reduced odds of long COVD among vaccinated (at least 2 COVID-19 vaccines) compared to unvaccinated (<2 vaccines) cases – applied to all vaccinated sub-groups.

OR = Odds ratio

Figure 2: COVID-19 YLDs resulting directly from Omicron cases during the first 4-months of the Omicron wave, December 10th 2021-April 9th 2022.

95% uncertainty intervals are shown for long COVID YLD estimates, measured with +/- 30% standard deviation.
Total morbidity (rightmost bar) is estimated at 7000 YLDs.
YLDs= Years Lived with Disability

Table 2: COVID-19 YLDs resulting directly from Omicron cases during the first 4-months of the Omicron wave, December 10th 2021-April 9th 2022.

Population group	YLD (95% UI [a])		
	Acute COVID-19	**Long COVID**	**Total**
Hospitalised adults (unvaccinated) [b]	43 (26-60)	431 (178-684)	498 (205-791)
Hospitalised adults (vaccinated) [b]	89 (54-124)	375 (154-595)	488 (201-774)
Non-hospitalised adults (unvaccinated)	425 (258-591)	1967 (810-3123)	2391 (985-3798)
Non-hospitalised adults (vaccinated)	867 (527-1207)	2197 (905-3488)	3064 (1262-4865)
Children (unvaccinated)	255 (155-355)	171 (70-271)	426 (176-677)
Children (vaccinated)	157 (95-218)	59 (24-94)	216 (89-343)
Total	**1835 (1116-2555)**	**5247 (2162-8333)**	**7035 (2898-11 171)**

[a] 95% UI estimated using +/- 30% standard deviation for long COVID and total YLDs, +/- 20% standard deviation for acute COVID-19 YLDs.

[b] For acute COVID-19 morbidity, hospitalised group included ICU and ward only calculations.

Note: figures presented in the text have been rounded from values in this table.

UI= Uncertainty Interval; YLD= Years Lived with Disability

Figure 3: Burden of disease comparison during the first 4 months of the Omicron wave (December 10th 2021- April 9th 2022), Australia.

Panel A: Comparison of the YLDs due to COVID-19 separated as long COVID (blue) and acute COVID-19 (red), to other outcomes (purple). Total COVID-19 YLDs = 7000 (95% uncertainty interval 2900-11 200). **Panel B:** Comparison of the DALYs due to COVID-19 separated as long COVID (blue) and acute COVID-19 (red), to other outcomes (purple). Total COVID-19 DALYs = 50 900 (95% uncertainty interval 21 000-80 900).

Note that COVID-19 YLDs and DALYs include the future morbidity resulting from long COVID for these cases. 95% uncertainty intervals are shown for COVID-19 DALY and YLD estimates (+/- 30% standard deviation). YLDs and DALYs for other outcomes are estimated from the 2019 GBD study, updated to the population size as of June 2021, and subsequently divided by three to estimate health loss over a four-month period.[15]

COPD= Chronic Obstructive Pulmonary Disease; CKD= Chronic Kidney Disease; T2DM= Type 2 Diabetes Mellitus; YLD= Years Lived with Disability.

*Total COVID-19 YLDS/DALYS include acute COVID-19 and long COVID.